Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,430 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Opioid Dependence
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Opiate Dependence
Interventions: Mobile Access; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Low Back Pain
Interventions: ABT-712, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 21 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 32
States / cities: Tempe, Arizona • Tucson, Arizona • Anaheim, California + 26 more

Conditions: Alcoholism
Interventions: ondansetron (Zofran), naltrexone (ReVia), Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain, Touch
Interventions: Placebo, Naloxone; Other · Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lumbar Spine Fusion, Pain, Back Pain
Interventions: Epidural Catheter - Dilaudid, Dilaudid; Other · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Interventions: Buccal swab saliva for further genetic testing; Genetic
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 1 Day to 5 Days
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Healthy
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Alcoholism, Alcohol Dependence
Interventions: naltrexone (Revia), cognitive behavior therapy, motivational enhancement therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2002
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pain
Interventions: Morphine, Methadone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcohol Dependence
Interventions: naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Opiate Dependence, Sexually Transmitted Diseases, HIV
Interventions: Acceptance and Commitment Therapy, Information Motivation Behavioral Model; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Osteoarthritis of the Knee
Interventions: ADL5859, ADL5747, Oxycodone CR, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Daytona Beach, Florida • Stockbridge, Georgia • Chicago, Illinois + 8 more

Conditions: Chronic Pain, Problematic Opioid Use
Interventions: Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU); Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 21 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Obsessive-Compulsive Disorder
Interventions: Fluoxetine 60 mg, Naltrexone 32 mg and fluoxetine 60 mg, Naltrexone SR 32 mg; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 11
States / cities: National City, California • San Diego, California • Gainesville, Florida + 8 more

Conditions: Opioid Use, Alcohol Drinking
Interventions: Alcohol, Opioid Agonist; Drug
Lead sponsor: Sharon Walsh; Other
Eligibility: 21 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Post-operative Pain Management
Interventions: Bupivacaine 0.25% Injectable Solution, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pontiac, Michigan

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions: Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN); Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Pain, Perioperative/Postoperative Complications, Sarcoma
Interventions: fentanyl citrate, hydromorphone hydrochloride, ropivacaine hydrochloride; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid Dependence, Pain, Addiction
Interventions: Placebo, Hydromorphone, Buprenorphine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Interventions: Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone; Drug
Lead sponsor: Yih-Ing Hser; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more

Conditions: Osteoarthritis
Interventions: hydrocodone / acetaminophen extended release, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 873 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 68 more

Conditions: Opioid-Related Disorders
Interventions: Behavioral: the OPT-IN Intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone

Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)

Sensory and Opioid Mechanisms of Affective Touch

Epidural Analgesia Versus IV Analgesia in Lumbar Spine Fusions

MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

Behavioral Therapy Plus Naltrexone for Alcoholism

Role of Methadone As Co-Opioid Analgesic

Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking

Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

The Behavioral Effects of Opioids and Alcohol

Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

Are Superficial Parasternal Intercostal Plane (SPIP) Blocks With Bupivacaine and With or Without Adjuvants Helpful for Post-operative Pain After Coronary Artery Bypass Grafting?

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

A Study of Pain Relief in Osteoarthritis

The OPT-IN Project